Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Update

Pulmatrix, Inc. (NASDAQ:PULM) saw a significant decrease in short interest in July. As of July 31st, there was short interest totaling 16,792 shares, a decrease of 38.9% from the July 15th total of 27,481 shares. Based on an average daily volume of 12,983 shares, the short-interest ratio is presently 1.3 days. Approximately 0.5% of the company’s shares are sold short.

Pulmatrix Stock Performance

Shares of PULM stock opened at $1.52 on Thursday. The stock has a market capitalization of $5.55 million, a P/E ratio of -1.38 and a beta of 1.91. The company has a 50 day moving average price of $1.63 and a 200 day moving average price of $1.73. Pulmatrix has a fifty-two week low of $1.16 and a fifty-two week high of $5.50.

Pulmatrix (NASDAQ:PULM) last released its earnings results on Thursday, August 13th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.00) by $1.71.

Institutional Trading of Pulmatrix

Several hedge funds have recently modified their holdings of the stock. DRW Securities LLC acquired a new position in Pulmatrix during the 4th quarter worth $46,000. Dimensional Fund Advisors LP acquired a new stake in Pulmatrix in the 3rd quarter valued at about $52,000. Finally, BlackRock Inc. acquired a new stake in Pulmatrix in the 2nd quarter valued at about $93,000. 11.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Pulmatrix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 14th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).